
    
      PRIMARY OBJECTIVES:

      I. To assess the percentage of patients able to successfully complete their prescribed
      treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an
      acceptable level of toxicity.

      SECONDARY OBJECTIVES:

      I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy,
      radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess
      2-year local control and progression-free survival.
    
  